Buyout PE
Great Point Partners
Great Point Partners acquires controlling stakes in established, profitable businesses, from Greenwich, Connecticut. It states a focus on healthcare & life sciences.
Stated investment criteria
What Great Point Partners says it buys
Read from Great Point Partners’s own website in August 2026. This is what the firm says it buys, not what anyone has recorded it buying, and figures are shown in the currency the firm itself used - nothing here is converted. Every line links to the page it was read from.
| Revenue it states | $10m to $100m1 |
| EBITDA it states | $2m to $12m1 |
| Transaction types | Add-on1 |
| Founded | 20033 |
| Offices | Greenwich, London4 |
| People listed on its team page | 342 |
Sources
A stated mandate is a firm’s description of itself and was true of the page on the day it was read; firms widen and narrow what they will look at without updating the site. Great Point Partners states that it will take either a controlling or a minority stake. The team figure counts the people the firm shows on one team page, so it is a floor rather than a headcount: firms that split their team across tabs or load it in pages will read low. Nothing here is a commitment by Great Point Partners to consider any particular business, and nothing on this page is represented as being for sale.
SEC filings
What Great Point Partners has raised
From this firm's own Form D filings. A fund files one within fifteen days of its first sale, under penalty of perjury, which makes these the hardest numbers on the page.
| Vehicles filed | 3 |
| Total capital raised | $594m |
| Largest single vehicle | $432m |
| Filing history | 2018 to 2021 |
| Smallest accepted commitment | $50k |
| Filed from | CONNECTICUT |
Form D covers US-domiciled vehicles raised from accredited investors. It will not capture a fund raised outside the United States, separately managed accounts, or capital deployed off balance sheet, so treat these as a floor rather than a total.
Regulatory record
How Great Point Partners is registered
From this firm's Form ADV, the annual filing every registered and exempt investment adviser makes to the SEC.
| Adviser status | SEC registered |
| Regulatory assets under management | $1.8bn |
| Employees | 28 |
| Private funds advised | 17 · $1.8bn gross |
| SEC adviser number | CRD 158423 |
Portfolio
Disclosed holdings
Companies Great Point Partners lists on its own website. 6 carry a stated investment year. 1 has a recorded transaction against it in the deal archive.
| Company | Invested | Years held | Recorded transaction |
|---|---|---|---|
| Biotronic NeuroNetwork | 2008 | 18 | $98m 2016 |
| Autism Learning Partners | 2010 | 16 | — |
| American Medical Staffing | 2011 | 15 | — |
| Axiom Real-Time Metrics | 2019 | 7 | — |
| Bionova Scientific | 2019 | 7 | — |
| Lenis | 2025 | 1 | — |
| Caprion | — | — | — |
| Cellipont | — | — | — |
| Citra Health | — | — | — |
| Connecture | — | — | — |
| Corrona | — | — | — |
| Cytovance | — | — | — |
| Electronic Therapy | — | — | — |
| Ephicacy | — | — | — |
| Equian | — | — | — |
| Eutecma | — | — | — |
| Family Resource Home Care | — | — | — |
| JPA | — | — | — |
| Lyocontract | — | — | — |
| MaSTherCell | — | — | — |
| NuVasive | — | — | — |
| Pyramids Pharmacy | — | — | — |
| Softbox Systems | — | — | — |
| Velentium Medical | — | — | — |
| VetnCare | — | — | — |
| Vālenz Health | — | — | — |
| amerisurg.com | — | — | — |
| arisradiology.com | — | — | — |
| axiommetrics.com | — | — | — |
| cellgro.com | — | — | — |
| csmondemand.com | — | — | — |
| ixcellsbiotech.com | — | — | — |
| littlespurspedi.com | — | — | — |
| mlm-labs.com | — | — | — |
| spineandsport.com | — | — | — |
| steripackgroup.com | — | — | — |
| terguspharma.com | — | — | — |
| vitalinkresearch.com | — | — | — |
Compiled from Great Point Partners’s published portfolio page. Where a recorded transaction is shown, that company was the target of a reported deal and has most likely already been realised. Nothing here is represented as being for sale.
Recorded transactions
Buying and selling
Deals in which Great Point Partners is named as buyer or seller in the transaction archive. 3 recorded exits, most recently in 2020. 1 recorded acquisition.
| Company | Side | Counterparty | Year | Consideration |
|---|---|---|---|---|
| MaSTherCell SA | Sold | Catalent | 2020 | $315m |
| Equian LLC | Sold | New Mountain Capital | 2015 | $225m |
| Cytovance Biologics | Sold | Shenzhen Hepalink Pharmaceutical Group Co. | 2015 | $206m |
| MaSTherCell SA | Bought | — | 2015 | $25m |
Compiled from a transaction archive of 10,204 recorded deals. Most private transactions are never disclosed, so this is a sample of a firm’s activity rather than a complete record of it.
Valuation context
Transaction values in Healthcare & Life Sciences
What companies have actually sold for in healthcare & life sciences, across 1,263 recorded transactions.
The full healthcare & life sciences picture - most active acquirers, recent transactions and every investor in the sector.
For owners
Own a healthcare & life sciences business?
The investors on this page acquire companies like yours. A confidential valuation costs nothing, commits you to nothing, and nobody is told you asked.
Request a confidential valuationFor investors
Is this Great Point Partners?
Claim this profile to correct anything wrong and tell us what you are looking for. We will send matching opportunities as they arise.
Claim or correct this profileTargeted buyer search
Which hundred of these would actually buy your business?
A researched shortlist with a verified deal-team contact for each, and the reason it is on the list. Fixed fee, from $1,450 - or we make the approach for you and hand you the conversations.
Comparable investors
Similar mandates
Other buyout pe investors active in healthcare & life sciences.